Toll Free: 1-888-928-9744

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2016

Published: Mar 30, 2016 | Pages: 216 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2016', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 9 Therapeutics Development 10 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 10 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 11 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 12 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 16 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 21 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 25 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 26 Aeolus Pharmaceuticals, Inc. 26 Angion Biomedica Corp. 27 Atox Bio Inc. 28 Avaxia Biologics, Inc. 29 Bolder Biotechnology, Inc. 30 Caladrius Biosciences, Inc. 31 Cellerant Therapeutics, Inc. 32 Cellphire, Inc. 33 Chrysalis BioTherapeutics, Inc. 34 Cleveland BioLabs, Inc. 35 Cumberland Pharmaceuticals, Inc. 36 Diffusion Pharmaceuticals Inc. 37 Eli Lilly and Company 38 GNI Group Ltd. 39 Humanetics Corporation 40 INSYS Therapeutics, Inc. 41 Meabco A/S 42 Neumedicines Inc. 43 Onconova Therapeutics, Inc. 44 PharmaIN Corporation 45 Pluristem Therapeutics Inc. 46 ProCertus BioPharm Inc. 47 RDD Pharma Ltd. 48 RedHill Biopharma Ltd. 49 RxBio, Inc. 50 Soligenix, Inc. 51 Stemedica Cell Technologies, Inc. 52 Terapio Corporation 53 Tonix Pharmaceuticals Holding Corp. 54 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Target 56 Assessment by Mechanism of Action 59 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 AB-103 - Drug Profile 66 ABC-294640 - Drug Profile 68 AEOL-10150 - Drug Profile 71 AEOL-10171 - Drug Profile 75 Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis - Drug Profile 76 AVMOC-001 - Drug Profile 77 AVX-470 - Drug Profile 78 BB-3 - Drug Profile 80 BBT-007 - Drug Profile 84 BBT-015 - Drug Profile 85 BBT-018 - Drug Profile 86 BBT-059 - Drug Profile 87 BCN-057 - Drug Profile 88 BIO-300 - Drug Profile 89 BMX-001 - Drug Profile 92 BPC-2 - Drug Profile 93 C-2E2 - Drug Profile 94 C-2E5 - Drug Profile 95 CBLB-613 - Drug Profile 96 CLT-009 - Drug Profile 97 EDL-2000 - Drug Profile 98 entolimod - Drug Profile 99 EWA-001 - Drug Profile 101 HSJ-0017 - Drug Profile 102 JP4-039 - Drug Profile 103 LGM-2605 - Drug Profile 105 LY-2109761 - Drug Profile 106 m2A2 - Drug Profile 107 NMIL-121 - Drug Profile 108 ondansetron hydrochloride - Drug Profile 110 ondansetron hydrochloride CR - Drug Profile 111 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 113 pirfenidone - Drug Profile 115 PLXR-18 - Drug Profile 116 PrC-210 - Drug Profile 119 RDD-2007 - Drug Profile 120 recilisib sodium - Drug Profile 121 Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 123 Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 124 Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 126 Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 127 RES-529 - Drug Profile 128 RP-239X - Drug Profile 131 rusalatide acetate - Drug Profile 132 Rx-100 - Drug Profile 136 RX-101 - Drug Profile 138 SGX-201 - Drug Profile 139 SGX-202 - Drug Profile 140 Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile 141 Small Molecules for Radiation and Chemical Toxicity - Drug Profile 142 Small Molecules for Radiation Toxicity - Drug Profile 143 Small Molecules to Activate Vitamin D Receptor for Radiation Injury - Drug Profile 144 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 145 ST-7 - Drug Profile 146 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 147 Stem Cell Therapy for Radiation Exposure - Drug Profile 149 SY-303A - Drug Profile 150 SY-513 - Drug Profile 151 SYGN-305P - Drug Profile 152 SYGN-399 - Drug Profile 153 Thrombosomes - Drug Profile 154 TPO-7630 - Drug Profile 155 TPO-7640 - Drug Profile 157 VEDA-1209 - Drug Profile 158 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates 159 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 199 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 203 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 204 Featured News & Press Releases 204 Appendix 211 Methodology 211 Coverage 211 Secondary Research 211 Primary Research 211 Expert Panel Validation 211 Contact Us 211 Disclaimer 212
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2016 14 Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Comparative Analysis by Unknown Stage Development, H1 2016 24 Products under Development by Companies, H1 2016 25 Products under Development by Companies, H1 2016 (Contd..1) 26 Products under Development by Companies, H1 2016 (Contd..2) 27 Products under Development by Companies, H1 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2016 29 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 30 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H1 2016 31 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Inc., H1 2016 32 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Avaxia Biologics, Inc., H1 2016 33 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H1 2016 34 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Caladrius Biosciences, Inc. , H1 2016 35 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H1 2016 36 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H1 2016 37 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H1 2016 38 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H1 2016 39 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H1 2016 40 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 41 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Eli Lilly and Company, H1 2016 42 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H1 2016 43 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H1 2016 44 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H1 2016 45 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2016 46 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H1 2016 47 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H1 2016 48 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H1 2016 49 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H1 2016 50 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H1 2016 51 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H1 2016 52 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H1 2016 53 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H1 2016 54 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H1 2016 55 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 56 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H1 2016 57 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 58 Assessment by Monotherapy Products, H1 2016 59 Number of Products by Stage and Target, H1 2016 61 Number of Products by Stage and Mechanism of Action, H1 2016 64 Number of Products by Stage and Route of Administration, H1 2016 67 Number of Products by Stage and Molecule Type, H1 2016 69 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016 163 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2016 203 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H1 2016 204 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H1 2016 205 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..3), H1 2016 206 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2016 207


List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2016 14 Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Products, H1 2016 23 Assessment by Monotherapy Products, H1 2016 59 Number of Products by Top 10 Targets, H1 2016 60 Number of Products by Stage and Top 10 Targets, H1 2016 60 Number of Products by Top 10 Mechanism of Actions, H1 2016 63 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 63 Number of Products by Top 10 Routes of Administration, H1 2016 66 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 66 Number of Products by Top 10 Molecule Types, H1 2016 68 Number of Products by Stage and Top 10 Molecule Types, H1 2016 68

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify